Allogene Therapeutics (ALLO) director receives 144,400 stock options grant
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Allogene Therapeutics director Stephen Mayo received a new stock option grant covering 144,400 shares of common stock. The options have an exercise price of $2.00 per share and vest in 12 equal monthly installments. Following this award, he holds options for 144,400 shares, expiring on June 18, 2036.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Mayo Stephen
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to buy) | 144,400 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to buy) — 144,400 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 144,400 shares
Exercise price: $2.00 per share
Shares after transaction: 144,400 options
+3 more
6 metrics
Option grant size
144,400 shares
Stock Option (Right to buy) awarded to Stephen Mayo
Exercise price
$2.00 per share
Conversion or exercise price of stock options
Shares after transaction
144,400 options
Total derivative shares following transaction
Expiration date
June 18, 2036
Option expiration date
Vesting schedule
12 equal monthly installments
Footnote describing option vesting
Transaction date
June 18, 2026
Date of option grant
Key Terms
Stock Option (Right to buy), Grant, award, or other acquisition, exercise price, vesting, +1 more
5 terms
Stock Option (Right to buy) financial
"security_title: Stock Option (Right to buy)"
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
exercise price financial
"conversion_or_exercise_price: 2.0000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"Vesting in 12 equal monthly installments."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: 2036-06-18T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
What did Allogene Therapeutics (ALLO) director Stephen Mayo report on this Form 4?
Stephen Mayo reported receiving a stock option grant for 144,400 shares of Allogene Therapeutics common stock. These options are a form of equity compensation and give him the right to buy shares at a fixed exercise price in the future.
What is the exercise price of Stephen Mayo’s new Allogene stock options?
The new options have an exercise price of $2.00 per share. This means Mayo can purchase Allogene common stock at $2.00 per share when he exercises the options, subject to vesting and the option’s expiration date.
How do Stephen Mayo’s Allogene stock options vest according to the filing?
The filing notes the options vest in 12 equal monthly installments. This schedule gradually makes portions of the 144,400-share award exercisable each month over one year, tying the benefit to continued service during that period.
When do Stephen Mayo’s newly granted Allogene stock options expire?
The options expire on June 18, 2036, giving a long-term exercise window. After that date, any unexercised portion of the 144,400-share grant will lapse and can no longer be used to purchase Allogene common stock.